Extracellular vesicles do not contribute to higher circulating levels of soluble 1 in idiopathic dilated cardiomyopathy by Rudilla, F et al.
Extracellular vesicles do not contribute to higher circulating
levels of soluble LRP1 in idiopathic dilated cardiomyopathy
Santiago Roura a, b, c , Carolina Galvez-Monton a, c, David de Gonzalo-Calvo c, d,
Ana Gamez Valero e, Paloma Gastelurrutia a, c, Elena Revuelta-Lopez a, Cristina Prat-Vidal a, c,
Carolina Soler-Botija a, c, Aida Llucia-Valldeperas a, Isaac Perea-Gil a, Oriol Iborra-Egea a,
Francesc E. Borras e, f, Josep Lupon c, g, h, Vicenta Llorente-Cortes c, d, i, *,
Antoni Bayes-Genis a, c, g, h, *
a Heart Failure and Cardiac Regeneration (ICREC) Research Program, Health Science Research Institute Germans Trias i Pujol
(IGTP), Badalona, Spain
b Center of Regenerative Medicine in Barcelona, Barcelona, Spain
c CIBERCV, Instituto de Salud Carlos III, Madrid, Spain
d Cardiovascular Research Center, CSIC-ICCC, IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
e Innovation in Vesicles and Cells for Application in Therapy Group, IGTP, Badalona, Spain
f Nephrology Service, Germans Trias i Pujol University Hospital (HUGTiP), Badalona, Spain
g Cardiology Service, HUGTiP, Badalona, Spain
h Department of Medicine, Barcelona Autonomous University (UAB), Barcelona, Spain
i Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
Received: December 20, 2016; Accepted: February 28, 2017
Abstract
Idiopathic dilated cardiomyopathy (IDCM) is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, and
low-density lipoprotein receptor-related protein 1 (LRP1) has been linked to the underlying molecular basis of the disease. This study compared
circulating levels of soluble LRP1 (sLRP1) in IDCM patients and healthy controls and elucidated whether sLRP1 is exported out of the myocardium
through extracellular vesicles (EVs) to gain a better understanding of the pathogenesis of the disease. LRP1 a chain expression was analysed in
samples collected from the left ventricles of explanted hearts using immunohistochemistry. sLRP1 concentrations were determined in platelet-free
plasma by enzyme-linked immunosorbent assay. Plasma-derived EVs were extracted by size-exclusion chromatography (SEC) and characterized
by nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (CD9, CD81) and myocardial (caveolin-
3) proteins and LRP1 a chain were assessed in SEC fractions by flow cytometry. LRP1 a chain was preferably localized to blood vessels in IDCM
compared to control myocardium. Circulating sLRP1 was increased in IDCM patients. CD9- and CD81-positive fractions enriched with membrane
vesicles with the expected size and morphology were isolated from both groups. The LRP1 a chain was not present in these SEC fractions, which
were also positive for caveolin-3. The increase in circulating sLRP1 in IDCM patients may be clinically valuable. Although EVs do not contribute to
higher sLRP1 levels in IDCM, a comprehensive analysis of EV content would provide further insights into the search for novel blood markers.
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Introduction
Dilated cardiomyopathy (DCM) is the most common cause of non-
ischaemic heart failure leading to heart transplantation [1]. In the
majority of cases, the primary cause is unknown, giving rise to the
term idiopathic dilated cardiomyopathy (IDCM). The most relevant
pathological and clinical traits include patchy interstitial fibrosis,
degenerated cardiomyocytes, marked cardiac endothelial deficits,
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ventricular chamber enlargement or dilatation, systolic dysfunction
with normal left ventricular (LV) wall thickness, progressive LV con-
tractile dysfunction, ventricular and supraventricular arrhythmias,
thromboembolism and sudden death [2–5].
Biomarkers are indicators of variation in normal and pathological
processes that are objectively measurable in biological systems or
samples [6]. As such they are becoming clinically helpful for assess-
ing survival time, as predictive tools in testing safety, toxicity and
therapeutic efficacy, for following disease progression, and to avoid
redundant treatments and related toxicities. The search for reliable
blood markers is ongoing in IDCM [7]. In this context, a variety of
biomarkers in distinct categories (myocyte stress and stretch, myo-
cyte apoptosis, cardiac interstitium, inflammation, oxidative stress,
cardiac energetics, neurohormones and renal biomarkers) have been
linked to heart failure, but only natriuretic peptides have been rou-
tinely adopted [8, 9]. However, others, including high-sensitivity tro-
ponin T and ST2, are currently being introduced into clinical practice
[10–12].
Low-density lipoprotein (LDL) receptor-related protein 1 (LRP1)
is a multifunctional receptor of the LDL receptor family that mediates
the clearance of a variety of structurally diverse extracellular mole-
cules [13]. LRP1 has a soluble form (sLRP1) [14–16], which can be
detected in the systemic circulation and other biofluids [17–19].
sLRP1 is composed of the a chain and a ~55-kDa fragment of the b
chain and is generated by endoproteolysis of the membrane b chain
segment [18, 20]. Recently, increased circulating sLRP1 levels have
been associated with severe hypercholesterolaemia [14] and epicar-
dial adipose tissue [21].
Thus, we sought to determine the myocardial expression and
localization of the LRP1 a chain and whether it preferentially binds
vessels in IDCM compared to control myocardium. We then com-
pared circulating levels of sLRP1 in plasma samples from IDCM
patients and healthy controls. Finally, we explored whether sLRP1 is
exported out of the myocardium via extracellular vesicles (EVs).
Materials and methods
Study population
Blood collection and plasma processing
Twenty IDCM patients from a multidisciplinary heart failure clinic and
15 age- and sex-matched healthy controls with no cardiovascular disor-
ders were enrolled for peripheral venous blood extraction. All laboratory
measurements were performed by experienced staff blinded to the
patients’ clinical characteristics. The main demographic and clinical
characteristics of the patients are summarized in Table 1. In particular,
all patients were selected in an ambulatory setting, and no one received
cathecolamine infusion close to the inclusion in the study. IDCM was
diagnosed by 2D echocardiography by standard methods. Left ventricu-
lar (LV) ejection fraction was calculated by the Simpson method using
2C and 4C views. Coronary angiography was performed in the need for
diagnosis of exclusion. Fourteen of the 20 patients had coronary
angiography. No coronary lesions were found in 12 of them, and one
single vessel disease, not considered causative of the dilated
cardiomyopathy, was found in two patients. The other six patients with-
out coronary angiography had absence of coronary symptoms and car-
diac SPECT or cardiac RN negative for ischaemic heart disease or null
suspicion of associated coronary disease. The duration of heart failure
was 68.3  60 months, median 40.6 (Q1–Q3 20.3–113.6). Also, none
of the patients in the study underwent heart transplantation along fol-
low-up, and there were just two women included with ages of 50 and
61 years. The study protocol was approved by the Clinical Research
Ethics Committee of our institution and conformed to the principles
Table 1 Demographic and clinical characteristics of idiopathic
dilated cardiomyopathy patients
n
Age, years 62.3  11.5 20
Male 18 (90) 20
Hypertension 10 (50) 20
Diabetes mellitus 9 (45) 20
Heart rate, bpm 71.3  9.4 20
Systolic blood pressure, mmHg 123.9  21.4 20
Diastolic blood pressure, mmHg 74.8  11.7 20
Ventricular end-systolic diameter 60.4  9.3 20
Ventricular end-diastolic diameter 49.5  7.9 20
Dyslipidemia 14 (70) 20
Total cholesterol, mg/dl 183.4  39.5 20
Triglycerides, mg/dl 145.1  89.2 19
LDL cholesterol, mg/dl 114.5  29.6 15
HDL cholesterol, mg/dl 49.6  18.8 16
LVEF 36.1  11.7 20








Data are presented as mean  S.D. or n (%).
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II
receptor blocker; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; LVEF: left ventricular ejection fraction; MRA: mineralocor-
ticoid receptor antagonist; NYHA: New York Heart Association.
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outlined in the Declaration of Helsinki. Written informed consent was
obtained from each participant.
Peripheral blood was collected following standard procedures that
minimize contamination by platelet-derived vesicles [22]. Isolated plate-
let-free plasma samples were frozen at 80°C until used in enzyme-
linked immunosorbent assays (ELISA) and purification of EVs.
Autopsy material
Full-thickness left ventricle (LV) collected from explanted IDCM hearts
(n = 9) and control hearts from non-cardiac decedents (n = 5) were
used for histomorphological analysis [4, 23, 24]. The demographic and
clinical characteristics of patients were previously summarized in detail
[24]. In brief, eligible IDCM criteria included non-ischaemic origin,
NYHA class II or higher, LV end-diastolic diameter ≥70 mm and LV
ejection fraction <25%, and neither evidence of myocarditis nor family
history of cardiomyopathy were reported. All patients were receiving
medical treatment according to the guidelines of the European Society
of Cardiology, with diuretics 89 %, angiotensin-converting enzyme inhi-
bitors 89 %, b-blockers 45 %, aldosterone antagonists 55 %, digoxin
55 % and statins 45 %, and total cholesterol and triglycerides levels
were 136.5 and 60.2 mg/dl, respectively. Non-diseased hearts were
mainly obtained from donors with neurological death caused by traffic
accident. The hearts were initially considered for cardiac transplantation
but were subsequently deemed unsuitable for transplantation either
because of blood type or size incompatibility. All donors had normal LV
function and no history of myocardial disease or active infection.
Comparatively, the demographic and clinical characteristics of
patients from whom blood and tissue samples were extracted were sim-
ilar except for the LV ejection fraction which was more depressed (15–
23.75%) in the myocardial tissue group as these patients were under-
going cardiac transplantation. All patients were also diagnosed with
IDCM by the same criteria.
Measuring sLRP1 levels
sLRP1 levels were measured using a commercially available ELISA
(Uscn Life Science Inc., Houston, TX) according to the manufacturer’s
instructions. The assay had a within- and between-assay variation coef-
ficient of <10% and 12%, respectively, and a limit of detection of
0.156 ng/ml. The assay showed no remarkable cross-reactivity or inter-
ference between sLRP1 and analogues. Associations between sLRP1
concentration, blood lipid parameters, and clinical variables were then
analysed.
Extracellular vesicle isolation and
characterization
Extracellular vesicles isolation by size-exclusion chromatography (SEC)
has been widely reported (Appendix S1) [25–30]. The size distribution
and concentration of plasma-derived EVs were determined by nanopar-
ticle tracking analysis (NTA) (Appendix S1). SEC-purified fractions
were also analysed for the presence of specific vesicular markers
(CD9 and CD81) [25], caveolin-3 and LRP1 a chain by flow cytome-
try, as described previously (Appendix S1) [28]. Finally, SEC fractions
with the highest mean fluorescence intensity (MFI) for exosomal
markers on a FACS-based assay were also selected for cryo-electron
microscopy [22].
Immunohistology and myocardial lipid content
analysis
Ten-millimetre-thick cryosections of LV samples were fixed with 4%
paraformaldehyde (Sigma–Aldrich, St. Louis, MO), permeabilized with
0.2% Triton X-100 (Sigma–Aldrich) and blocked in 20% horse serum
(Invitrogen, Carlsbad, CA) for 1 hr at room temperature. Cryosections
were stained using antibodies against human LRP1 a chain (1:50; Invit-
rogen), cardiac troponin I (cTnI) (1:200; Santa Cruz Biotechnology, Inc.,
Dallas, TX), von Willebrand Factor (vWF) (1:100; BD Pharmingen, San
Diego, CA) and CD31 (1:50; Abcam, Cambridge, UK), and with biotiny-
lated GSLI B4 isolectin (1:50; Griffonia simplicifolia lectin I B4; Vector
Labs, Burlingame, CA). Alexa Fluor 488-conjugated streptavidin and
Cy2, Cy3 and Cy5 (1:500; Jackson ImmunoResearch Laboratories, West
Grove, PA) secondary antibodies were also used. All sections were
counterstained with 4’,6-diamidino-2-phenylindole dihydrochloride
(DAPI) (1:10 000; Sigma-Aldrich) and analysed by confocal microscopy
(Axio Observer Z1; Zeiss, Oberkochen, DE). Quantitative immunohisto-
chemical measurements were completed with the Image-Pro Plus soft-
ware (6.2.1 version; MediaCybernetics, Rockville, MD).
On 4-lm paraffin slices, Picrosirius red staining was performed to
analyse collagen (Col) volume fraction (CVF), and Col type I (red/yellow)
and Col type III (green) under a computer-associated Leica DMI 6000B
microscope with a polarized filter.
One aliquot of frozen tissue (10 mg) was homogenized in 0.1 M
NaOH for lipid content extraction. Subsequently, the amounts of choles-
teryl ester (CE), free cholesterol (FC) and triglyceride (TG) were anal-
ysed by thin layer chromatography as described previously
(Appendix S1) [23].
Statistical analysis
Data are presented as mean  S.D. Kolmogorov–Smirnov analysis was
used to check for normality of data. Statistical analyses were performed
using the Student’s t-test, and the Mann–Whitney test for non-para-
metric data, using SPSS 19.0.1 (SPSS, Inc., Chicago, IL). Associations
between sLRP1 and blood lipid levels or clinical variables were
assessed by Pearson correlation for continuous variables and linear
regression for categorical variables. Differences were considered signifi-
cant when P < 0.05.
Results
LRP1 a chain is preferentially localized in the
myocardial vasculature in IDCM patients
First, to confirm fibrosis as a hallmark of failing hearts, we measured
myocardial deposition of collagen (Col) by staining with Picrosirius
red (Fig. S1). A significant CVF accumulation was found in IDCM
compared to control myocardium (P = 0.048). Additionally, increased
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Col I and Col III amounts were also found in IDCM patients
(P = 0.045 and P = 0.005, respectively).
To explore whether plasma sLRP1 levels are potentially valuable
for IDCM, we then assessed myocardial expression of LRP1 a chain
using immunohistochemistry. Higher amounts of LRP1 a chain were
found in myocardium from IDCM patients compared to controls
(P = 0.02) (Fig. 1). Remarkably, LRP1 a chain also localized differ-
ently between the two groups. In IDCM, LRP1 a chain was mainly
found in myocardial vessels positive for isolectin B4, vWF or CD31
and, thus, more exposed to the systemic circulation (Fig. 1).
Subsequently, because LRP1 endoproteolysis and secretion has
been linked to hypercholesterolaemic conditions, we investigated
possible differences in the myocardial lipid content. As shown in
Figure 2, although TG content significantly increased in patients
compared to controls (P = 0.026), no differences in CE or FC
amounts were found between the groups (P = 0.16 and P = 0.35,
respectively).
Circulating sLRP1 levels are higher in IDCM
patients than controls
Next, we analysed sLRP1 levels in platelet-free plasma. As shown in
Figure 3, ELISA analyses revealed significantly higher levels of sLRP1
in plasma from IDCM patients compared to controls (P = 0.034). To
evaluate a possible association or relationship between increased
sLRP1 levels and hypercholesterolaemia, we focused on blood lipid
parameters. Interestingly, we found no association between sLRP1
levels and any of the lipid parameters, including cholesterol
(r = 0.04, P = 0.87), TGs (r = 0.15, P = 0.53), HDL (r = 0.11,
P = 0.67) and LDL (r = 0.20, P = 0.47). Preliminary analyses also
revealed no correlation between sLRP1 concentrations and clinical
variables, such as LV ejection fraction (r = 0.35, P = 0.13), age
(r = 0.004, P = 0.99), sex (P = 0.37), diabetes mellitus (P = 0.27),
hypercholesterolaemia (P = 0.73), NYHA functional class (P = 0.86)
and statin treatment (P = 0.14).
Fig. 1 Analysis of myocardial LRP1 a chain expression and localization. Representative confocal microscope images showing specific global
detection of LRP1 a chain (red) (A) and more detailed localization of LRP1 a chain (green) in IsoB4—(grey) (B), CD31—(grey) (C and D) and vWF
—(grey) (E) positive vessels. Cardiac muscle and cell nuclei are counterstained using an anti-cTnI antibody (red) and DAPI (blue), respectively.
Scale bars = 50 lm (F) Histogram represents quantification of LRP1 a chain positivity as percentage of arbitrary units per area. *P = 0.02.
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LRP1 a chain is not secreted via EVs
To examine whether sLRP1 is exported out of the myocardium
through EVs, methodology based on SEC was applied to platelet-free
plasma samples from both groups. SEC fractions were assessed by
flow cytometry for enrichment with the EV-related proteins CD9 and
CD81. In particular, no differences in the measured levels of these EV
markers were found between groups (P = 0.43 and P = 0.97 for CD9
and CD81, respectively). The set of fractions with the highest MFI val-
ues for CD9 and CD81 were then separated from the bulk of plasma
proteins. Remarkably, the myocardial protein caveolin-3 was detected
in these fractions, but not LRP1 a chain in both groups (P = 0.99)
(Fig. 4A).
Further analysis of the EV-enriched fractions comprised assess-
ment of the particle size distribution/concentration by NTA of the mor-
phology and structure and cryo-transmission electron microscopy to
analyse the size range. Examination of representative images taken of
the distinct SEC fractions confirmed the presence of membranous
vesicles ranging from 40 to 300 nm in the fractions positive for vesic-
ular markers, whereas non-EV-enriched fractions had an abundance
of small electron-dense particles lacking a discernible membrane
bilayer, which most likely represent lipoproteins (Fig. 4B) [31]. We
also recognized particles within the expected size range of EVs with-
out differences between groups (Fig. 4C).
Discussion
The results from the present study indicate for the first time that the
measurement of peripheral sLRP1 is potentially valuable for IDCM.
Furthermore, as first approach, sLRP1 seems to be released to the
circulatory system independent of the exosome pathway.
The protease inhibitor protein a-2 macroglobulin, which is highly
increased in the myocardium of IDCM patients [24], was one of the
first LRP1 ligands described [32]. In IDCM, specific cardiac alter-
ations are produced mainly by an adverse remodelling of the left
Fig. 2 Assessment of myocardial lipid content. Distribution of cholesteryl esters (CE), triglycerides (TG) and free cholesterol (FC) in both groups
(St = standard, C = control and D = dilated cardiomyopathy). Histograms represent the quantification of total TG, CE and FC. n = 5 each control
and idiopathic dilated cardiomyopathy (IDCM). *P = 0.026.
Fig. 3 Increased levels of circulating sLRP1 in idiopathic dilated car-
diomyopathy (IDCM) patients. The histogram represents quantification
of circulating sLRP1 by ELISA. *P = 0.034. n = 15 control and n = 20
IDCM.
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ventricle [33–35], where the activity of extracellular matrix metallo-
proteinases (MMPs) is deeply altered [36, 37]. Increased activation of
MMPs and negligible levels of specific MMP inhibitors are closely
associated with the disease [30, 33, 38–40]. Furthermore, one of the
key LRP1 molecular relays is the mitogen-activated protein kinase/ex-
tracellular signal-regulated kinase (ERK) pathway [41–43]. Excessive
ERK signalling has been reported in IDCM patients [24, 44] and in
experimental models of the disease [45]. Data from our laboratory
have also shown the redistribution and over-activation of LRP1 within
the localized, cholesterol- and glycosphingolipid-enriched regions
within plasma membranes, termed lipid rafts, in myocardium from
IDCM patients, as well as a concomitant increase in non-raft-related
ERK1,2/MMP9 [24]. Regarding myocardial levels of LRP1, although
no statistical differences between IDCM and control hearts were pre-
viously found in our laboratory using a specific anti-LRP1 b chain
antibody [24], we here reveal that expression of LRP1 a chain is sig-
nificantly promoted in IDCM. Moreover, whereas LRP1 b chain seems
to be agglutinated in cardiac myocytes indistinctly in patients and
Fig. 4 sLRP1 is not found in platelet-free plasma-derived extracellular vesicles (EV) fractions. (A) Representative analyses of platelet-free plasma-
derived size-exclusion chromatography (SEC) fractions by flow cytometry. Median fluorescence intensity (MFI) was measured, and the isotype nega-
tive control is represented as a dashed line. (B) Electron micrographs of vesicular protein-enriched (8–10) and non-enriched (11–13) fractions from
a healthy control (left) and a idiopathic dilated cardiomyopathy (IDCM) patient (right) showing multifaceted assembly of round electron-lucent mem-
brane vesicles and a large quantity of smaller electron-dense structures lacking a membrane bilayer, respectively. (C) Characteristic particle size dis-
tribution and concentration by NTA (healthy control, left; IDCM, right). n = 5 each control and IDCM. Scale bars = 100 nm.
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controls, LRP1 a chain is mostly found in myocardial vessels in
IDCM. These findings point out to complex cell-specific regulatory
mechanisms for the expression (and maybe assembly and cleavage)
of the subunits conforming the LRP1 receptor.
The levels of circulating sLRP1 are significantly higher in patients
with severe hypercholesterolaemia than in patients with moderate
hypercholesterolaemia and normocholesterolemic controls [14]. The
association between circulating sLRP1 levels and pro-atherogenic
lipoproteins, including LDL cholesterol, is reproducible in different
hypercholesterolaemic populations, suggesting their causality. High-
cholesterol diet and cholesterol-lowering strategies also modulate
inversely both vascular LRP1 expression and lipid content in the arte-
rial intima [46], and atheroprotective strategies exert benefits related
to increased communication between endothelial and smooth muscle
cells via EVs [47]. In the present study, however, we did not find a
significant association between blood lipids and sLRP1 levels. A com-
prehensible explanation for this lack of association is that our patients
cohort showed lower levels of LDL cholesterol to those in which this
effect has been described (i.e. >190 mg/dl) [14]. Furthermore, our
preliminary analysis revealed no correlation between sLRP1 concen-
trations and treatment with statins. Nevertheless, additional work is
warranted to evaluate the effects of atheroprotective strategies in the
release and specific content of EVs carrying endothelial cell markers.
On the other hand, we have recently identified circulating sLRP1
as a novel biomarker of epicardial adipose tissue [21]. Nevertheless,
patients with congestive heart failure show significantly reduced
amounts of epicardial adipose tissue compared to healthy individuals
irrespective of the underlying aetiology of the cardiomyopathy [48,
49]. Thus, despite epicardial adipose tissue was not quantitative mon-
itored in our cohorts, it seems that this parameter would not play a
role in determining circulating sLRP1 in this condition. At the histo-
logical level, a precise examination of myocardium afflicted by IDCM
confirmed the characteristic hallmarks, such as altered cardiac mus-
cle integrity, myocyte atrophy, and increased deposition of collagen
and lipids around myocardial filaments [50]. We also showed that the
TG content is higher in myocardium from IDCM patients than control
subjects. In contrast, myocardial CE levels were extremely low and
similar to controls. Although some pharmacological treatments might
influence these findings, they may be related to a range of well-
reported metabolic dysfunctions, including altered fatty acid uptake
and oxidation in failing hearts [51, 52]. Thus, extra- or intra-myocar-
dial cholesterol does not seem to be related to higher sLRP1 release
to the plasma of IDCM patients. Previously, plasma sLRP1 was
shown to antagonize ligand endocytosis by cellular LRP1 in the lungs
of patients with acute respiratory distress syndrome [19], preventing
the cellular clearance of MMPs. A similar mechanism may contribute
to tissue remodelling in IDCM. Thus, we sought to determine whether
LRP1 cleavage and secretion is promoted in the circulatory system in
IDCM patients. We found that circulating levels of sLRP1 are signifi-
cantly increased in patients with IDCM, but future investigations are
warranted to elucidate whether LRP1 shedding is promoted or sLRP1
clearance is decreased in this condition.
In the present study, we also assessed whether LRP1 is exported
out of the myocardium via the EV pathway. EVs include a wide range
of lipid membrane vesicles secreted by all types of cells, distinctive in
size, biogenesis, cargo molecules and function [53]. After being
secreted upon the fusion of multivesicular bodies with the plasma
membrane, EVs play central roles in a variety of processes, including
intercellular communication, recycling of membrane proteins and
lipids, immunomodulation, senescence, angiogenesis, proliferation,
differentiation and migration. Interestingly, shed under both normal
and pathological conditions, EVs have been found in different biologi-
cal fluids (e.g. blood, urine, saliva) and are considered relevant diag-
nostic tools and a key source of biomarkers [54]. Thus, the role of
EVs in cardio-metabolic diseases has been widely studied in the last
few years [55]. To our best knowledge, this is the first study to
assess the presence of sLRP1 in plasma-derived EVs extracted by
SEC technology. Although LRP1 is preferentially detected at the intra-
cellular level using detergent-based analytical techniques such as
Western blot or immunocytochemistry, some previous studies have
measured its cellular expression levels in standardized flow cytometry
assays [56, 57]. Using SEC, protein content was undetectable in SEC-
pooled EV fractions (fractions 8-10), as most of the soluble proteins
eluted in later fractions (fraction 13 onwards). This finding confirms
SEC as the cleanest method to isolate EV-enriched samples removing
most of the over-represented plasma proteins for subsequent sophis-
ticated analysis such as proteomics [30]. Indeed, our analyses sug-
gested that LRP1 is not associated with this type of circulating EVs
and that these EVs seem to contain the specific myocardial marker
caveolin-3 [24]. Currently, together with the fact that we cannot
assume that these peripheral EVs are entirely exported out from myo-
cardium, this finding counteracts the possibility of tracking the exact
origin of the sLRP1 found in circulation. Thus, we cannot exclude the
possibility that sLRP1 is released from other body sources. To that
end, future studies and funding priorities should include the analysis
of EVs comprised in blood samples from the coronary sinus and how
sLRP1 elutes later in non-EV fractions (fractions 11-13), when protein
amount is extremely low. Although we cannot exclude some associa-
tion with carrier proteins and/or small lipoprotein particles, we also
speculate that this is caused in part by the high molecular weight of
LRP1 a chain (~515 kDa).
As a limitation, our study included blood samples collected from
ambulatory patients and myocardial tissue specimens extracted from
patients undergoing heart transplantation. Thus, analysis of speci-
mens collected from the same group of patients, preferably in those
undergoing heart transplantation, should be recommended to further
confirm the clinical value of sLRP1 measurement. Nevertheless, our
study opens new doors for further comprehensive analysis of the
cargo of these EVs release into the systemic blood of IDCM patients.
Additional studies with a higher number of EV samples for each group
should be performed to corroborate these preliminary results. For
instance, proteomics analysis could support our findings and provide
additional information on the molecular basis of the disease and
assist in the search for novel blood markers with robust diagnostic
and prognostic value [25].
In summary, our results support that endoproteolysis and secre-
tion of LRP1 is promoted in IDCM and that circulating levels of its sol-
uble form may be a potentially helpful measurement. Moreover,
sLRP1 appeared to be secreted independently of EVs, a fact that does
not favour a precise identification of its origin. In line, specific in vivo
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models of disease (e.g. pacing-induced heart failure animal models)
are needed to establish the exact mechanism and provenance of
sLRP1 release. As mentioned previously, it will be crucial to validate a
versatile clinical utility for the measurement of sLRP1 in larger
cohorts of patients with IDCM. To that end, large, well-designed, mul-
ti-centre, collaborative studies are central to showing that it can be a
highly sensitive and cost-effective measurement with reliable clinical
value. Further insights into the potential associations between sLRP1
concentrations, levels of EVs in circulation, cardio-metabolic dis-
eases, epicardial adipose tissue, clinical variables and/or events, car-
diac function parameters or degree of tissue damage are also
mandatory. We also highlight the need for continual development of
analytical techniques to permit quantitative comparisons of EV levels
in circulation, as new data are collected. As the number of functional
studies on EVs increases, innovative workflow technical platforms are
necessary to specifically characterize surface and cargo proteome. In
this way, it is crucial to determine the detailed orientation and topol-
ogy of proteins (e.g. LRP1 and their proteolytically cleaved forms) on
or inside of EVs before they can reach clinical significance as
biomarkers for disease. Particularly, in IDCM, biomarker research is
in the early development stage and the usefulness of EVs and the
recognition of their specific combinations of proteins, lipids and miR-
NAs as possibly helpful clinical tools has enormous potential.
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